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Herein, we studied the cross talk between 5-HT2B receptor blocker (SB-204741) and GSK-3b inhibitor
(SB-216763) in isoproterenol-induced cardiac hypertrophy for 28 days. SB-204741 treatment signif-
icantly ameliorated (P < 0.05) myocardial dysfunction, myocyte area, ﬁbrosis and myocardial archi-
tecture in isoproterenol insulted myocardium. Moreover, this improvement in functional and
morphological changes was associated with suppression of hypertrophic (BNP and CK-MB), inﬂam-
matory (IKK-b/NF-jB/TNF-a and CRP), and apoptotic markers (TUNEL positivity and Bax expression)
along with phosphorylation of Akt/GSK-3b/b-catenin/eNOS. Intriguingly, co-treatment with GSK-3b
inhibitor (P < 0.01) further ampliﬁed the anti-hypertrophic effect of SB-204741 (P < 0.05) such that
the effect was indistinguishable from that of vehicle treated rats. Thus, 5-HT2B receptor blockade
mediated anti-hypertrophic effect is atleast in part is governed through phosphorylation of Akt/
GSK-3b/b-catenin/eNOS via attenuating inﬂammatory and apoptotic pathways.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Physiological and pathological stimulation of heart led to archi-
tectural remodeling that result in molecular reprogramming of var-
ious proteins. One of the direct consequences of this stimulation is
anactivationof various signalingpathways leading to cardiachyper-
trophy. Especially, protein kinase B (Akt/PKB)-glycogen synthase ki-
nase-3b (GSK-3b) is one of the pathways which actively participate
in regulating hypertrophic effect in response to exogenous stimuli.
GSK-3b being a direct substrate of Akt, arbitrates various cellular
processes such as cardiac development, growth, protein synthesis,
and gene transcription. Moreover, phosphorylation/inhibition of
GSK-3b upregulates cellular defense mechanism by maintaining
the cytoskeletal architecture, redox homeostasis, and shielding the
cell from spontaneous or stimulated programmed cell death [1].
In recent years, several lines of evidence suggest that serotonin is
an important neurohormonal factor that regulates cardiomyocyte
growth, proliferation, contractility and hemodynamic functions
[2]. Moreover, it has been demonstrated that, of all the 5-HT recep-
tors subtypes, 5-HT2B receptor blockade (5-HT2BRB) emerged as the
strongest candidate in ameliorating cardiac hypertrophy, thoughchemical Societies. Published by E
).the molecular signaling pathways driving this activity are hitherto
largely unknown [3].
On the basis of the aforementioned facts, we hypothesized that
GSK-3b, amultifunctional Serine/Threoninekinase that signiﬁcantly
contributes in the survival and demise of cardiomyocytes; at least in
part, plays a role in 5-HT2BRB mediated anti-hypertrophic effect.
Accordingly, this study was attempted to dissect the complex
molecular, and functional pathophysiology of 5-HT2BRB mediated
anti-hypertrophic response by evaluating: (1) whether isoprotere-
nol-inducedmyocardial hypertrophy is associatedwith 5-HT2B over
expression or downregulation, (2) if so, can its modulation by spe-
ciﬁc agonist or antagonist ameliorate cardiac hypertrophy and (3)
whether this anti-hypertrophic response can be modulated by
GSK-3b inhibition, through arbitrating Akt/GSK-3b/b-catenin/eNOS
pathway.
2. Materials and methods
5-HT2BR antagonist (SB-204741) and GSK-3b inhibitor, GSK-3bi,
(SB-216763) were purchased from the Sigma Chemicals (St. Louis,
MO, USA). NF-jB, MnSOD and Nox4 antibodies were purchased
from Abcam Technology, USA and all other primary and secondary
antibodies were purchased from Santa Cruz Biotechnology, USA.
Rat TNF-a (Diaclone Tepnel Company, UK), Brain Natriureticlsevier B.V. All rights reserved.
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react, Spain), and C-reactive protein (CRP) (Bender MedSystems
Inc., A-1030 Vienna, Austria) ELISA kits were used. SB-204741
and SB-216763 were freshly prepared and dissolved in DMSO
and propylene glycol (2:1) before administration.
2.1. Animals
The protocol was approved by the Institutional Animal Ethics
Committee (Approval No. 567/IAEC/2010) and all study related
activities conformed to the IndianNational Science AcademyGuide-
lines for the use and care of experimental animals in research.
2.2. Experimental protocol
Male wistar rats (150–170 g) were divided into ﬁve groups
(n = 8) and were administered vehicle or drugs for 28 days. The
doses of the test drugs were determined based on the previous
studies [4,5].
Group 1 (NC): vehicle (0.3 ml, i.p.).
Group 2 (ISO): isoproterenol (3.0 mg/kg/day, s.c.).
Group 3 (ISO + SB): isoproterenol (3 mg/kg/day, s.c.) plus SB-
204741 (1.0 mg/kg/day, i.p.).
Group 4 (ISO + SB + GSK-3bi): isoproterenol (3 mg/kg/day, s.c.)
plus SB-204741 (1.0 mg/kg/day, i.p.) plus SB-216763 (0.6 mg/
kg/day, i.p.).
Group 5 (SB + GSK-3bi): SB-204741 (1.0 mg/kg/day, i.p.) plus
SB-216763 (0.6 mg/kg/day, i.p.), per se treated group.
The results of group 5 did not show any signiﬁcant change in
any of the parameters as compared to sham group; therefore we
did not include the data of this group as it would add to the exist-
ing space.
2.3. Surgical procedures for evaluating hemodynamic parameters
The detailed surgical procedure for measuring hemodynamic
parameters has been described in our previous study [6]. After
recording the hemodynamic parameters, animals of all the groups
were sacriﬁced with an overdose of anesthesia (sodium pentobar-
bitone 100 mg/kg, i.v.) and their hearts were excised and processed
for various parameters. In addition, blood was withdrawn via
cardiac puncture and centrifuged at 3000g for 5 min for measuring
serum CK-MB, CRP and BNP levels.
2.4. Biochemical estimation
A 10% homogenate of myocardial tissue was prepared in ice-
chilled phosphate buffer (50 mM, pH 7.4) and an aliquot was used
to estimate malondialdehyde (TBARS) [7] and glutathione peroxi-
dase (GSHPx) levels [8]. Furthermore, homogenate was centrifuged
at 5000g for 20 min at 4 C and the supernatant was assayed for
protein content and TNF-a levels.
2.5. Western blot analysis
Left ventricular tissue protein samples (40 lg) were separated
by sodium dodecyl sulfate-polyacrylamide gel electrophoresis,
transferred to nitrocellulose membrane which was blocked for
2 h with 5% bovine serum albumin and incubated for 24 h at 4 C
with a rat primary antibody b-actin, 5-HT2B, Bcl2, Bax (1:2500);
eNOS, P-eNOS (Ser1177), Akt, P-Akt (Ser473) (1:2000); GSK-3b,
P-GSK-3b (Ser9) (1:1500); NF-jBp65 chip grade, IKK-b (Ser180),
Nox4, and MnSOD (1:1000). The primary antibody was detected
with horse radish peroxidase-conjugated secondary antibody goatanti-rabbit/goat anti-mouse (1:1000). The blots so obtained were
scanned and densitometry was performed to quantify the expres-
sion using Bio-Rad Quantity One 4.4.0 software (Bio-Rad, Hercules,
CA).
2.6. Terminal deoxynucleotidyl transferase dUTP nick end labeling
(TUNEL) assay
TUNEL assays were performed using an in situ cell death detec-
tion kit, POD (Roche, Germany) following the manufacturer’s
instructions.
2.7. Histopathological and transmission electron microscopy analysis
Histopathological and ultrastructural analysis of heart tissues
were performed by the method described previously [6]. Brieﬂy,
the hearts were cut (3 lm thick) using microtome (Leica RM
2125, Germany) and stained with Hemotoxylin and Eosin for any
histopathological changes or masson trichome staining (green-
brown) for interstitial and ﬁbrosis. For analyzing myocyte
cross-sectional area, sections were stained for membranes with
FITC-conjugated Wheat Germ Agglutinin (pictomicrographs not
shown) (Nikon, Image Pro-Plus 4.0 software). The outline of 100
myocytes was traced in each section. The pathologist performing
histopathological and ultrastructural analysis was blinded to the
treatment protocol.
2.8. Statistical analysis
The data is presented as mean ± S.D. and one way ANOVA fol-
lowed by Bonferroni post-hoc test was used to compare the groups.
The histopathological grading was expressed as median score and
Kruskal–Wallis test was employed to compare the groups. Value of
P < 0.05 was considered signiﬁcant.3. Results and discussion
While there is strong evidence that 5-HT2BRB negatively regu-
lates cardiac hypertrophy [2–4], the molecular pathways driving
this activity are hitherto largely unknown. It has been well docu-
mented that Akt/GSK-3b/b-catenin/eNOS is a crucial component
of biochemical pathway responsible for cardiac hypertrophy
induced by isoproterenol. Therefore, to establish whether this cen-
tral hypertrophic pathway is the key regulator of cardioprotective
potential of 5-HT2BRB, it will be imperative to analyze its relation
with Akt/GSK-3b/b-catenin/eNOS pathway. Accordingly, our ﬁnd-
ings demonstrated that (1) the protective effect of SB-204741, a
5-HT2BRB is associated with the upregulation of P-Akt/P-GSK-3b/
b-catenin/P-eNOS expressions and (2) which was coupled with
shutting down of the inﬂammatory (decreased IKK-b/NF-jB/TNF-
a expressions) and apoptotic markers (decreased Bax expression
and TUNEL positivity and increased Bcl-2 expression). Intriguingly,
we also found that SB-216763, a GSK-3bi further augmented this
anti-hypertrophic effect, thereby, conﬁrming the crucial role of
GSK-3b in our hypothesis. Taken together, the anti-hypertrophic
response of 5-HT2BRB is at least in part is governed by augmented
Akt/GSK-3b/b-catenin/eNOS phosphorylation.
In our study, 5-HT2BRB abrogated the isoproterenol-induced car-
diac hypertrophy as evidenced by signiﬁcantly (P < 0.05) decreased
HW/BW ratio (4.71 ± 0.58 vs. 7.51 ± 0.41 mg/g), LV/BW ratio
(4.2 ± 0.7 vs. 5.92 ± 0.45 mg/g), myocyte area (213.64 ± 32.75 vs.
321.5 ± 55.89 lm2) and interstitial ﬁbrosis (2.9 ± 0.52 vs.
4.8 ± 0.65; fold change) as compared to isoproterenol controls
(Fig. 1A–D). Moreover, this preserved cardiac architecture was well
corroborated with cardiac performance as typiﬁed by signiﬁcant
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79.5 ± 10.2 mmHg), left ventricular end diastolic pressure (4.5 ±
0.4 vs. 7.24 ± 0.4 mmHg), inotropic status, +LVdP/dtmax
(3683.75 ± 194.2 vs. 2899.5 ± 152.8 mmHg/s) and lusitropic status
LVdP/dtmax (2698.4 ± 168.2 vs. 2090.4 ± 220.5 mmHg/s) along
with no effect on heart rate (362.5 ± 30.4 vs. 382.6 ± 28.5 beats/
min) as compared to isoproterenol controls (1F–1J). Surprisingly,
SB-216763, ampliﬁed the anti-hypertrophic effect of SB-204741 as
manifested by a superior improvement (P < 0.01) in hemodynamic
and ventricular functions. Likewise, histopathological and ultra-
structural studies displayed lesser myonecrosis, interstitial ﬁbrosis,
inﬁltration of inﬂammatory cells, ﬁber disarray, mitochondrial
swelling, widened I band, distorted Z line and chromatin condensed
apoptotic nuclei as compared to SB-204741 treated group (Fig. 3:
A1–A4, B1–B4, D1–D4 and Table 1B).
The corollaries of hypertrophied myocardium can range from
damage to multiple loci within the cell to impaired contractile
function. The former outcome is represented by down-regulation
of various cytoprotective and cytoskeletal proteins and proteolysis
of actin ﬁlaments (impaired excitation–contraction process);
whereas the latter process is ensued by increased pre- and after
load, inadequate ventricular emptying, reduced cardiac output
and ultimately heart failure. So, to prevent the cardiomyocyte
demise, phosphorylation of Akt/GSK-3b, a crucial switch gets
upregulated and subsequently tunes various other cytoprotective
genes to arrest the progression of cardiomyocyte insult [1]. This
was exactly what we observed in our ﬁndings which might be a
probable reason for superior anti-hypertrophic effect in SB-
216763 group as compared to SB-204741 group. Firstly, thisFig. 1. Effect of drugs on (A) heart weight body weight ratio (HW/BW ratio); (B) left ventr
apoptotic nuclei; (F) mean arterial pressure (MAP); (G) heart rate (HR); (H) left ventricula
rate of relaxation (LVdP/dtmax) (n = 8). ⁄P < 0.01 versus NC and P < 0.05, §P < 0.01 verampliﬁed phosphorylation/inhibition of Akt/GSK-3b activates sar-
coplasmic reticulum Ca2+ATPase 2a (SERCA2a) channel resulting
in improved calcium homeostasis (by attenuating intracellular
calcium overload), diastolic function and inotropic reserve of the
myocardium [1,9,10]. Secondly, GSK-3bi prevents the decline in
ATP and alleviates overall cell survival by inhibiting mitochondrial
permeability transition pore [1,5,11]. Finally, Akt/GSK-3b phos-
phorylation/inhibition also preserves actin-myosin cross-bridge
cycling; thus improving contractility and hemodynamic status of
the recovered myocardium [1,9].
Therefore, the ﬁndings obtained from our study, allow us to
postulate that enhanced phosphorylation of Akt/GSK-3b/eNOS by
GSK-3bi may be a key step in anti-hypertrophic effect of 5-HT2BRB.
Notably, SB-216763 also enhanced b-catenin expression better
than SB-204741 which might account for maintaining a more sus-
tained cell–cell adhesive interaction in SB-216763 group as it has
been demonstrated that mice overexpressing b-catenin had
decreased myocyte area and a blunted hypertrophic response to
angiotensin-II, with a resultant improved synergy of contraction
[12,13]. Likewise, an eNOS deﬁcient mouse exhibited signiﬁcantly
increased cardiac hypertrophy, proinﬂammatory cytokines and
decreased SERCA2a mRNA levels [14]. Another unifying mecha-
nism in the protective effect of SB-204741/SB-216763 lies in the
inhibition of L-type calcium channel [4,15] or phosphorylation of
Akt/GSK-3b/eNOS and stabilization of transcription factor b-cate-
nin in the failing heart [9,15]. Perhaps, an overexpression of Bcl2
by SB-216763 over SB-204741 might also account for enhanced
cardioprotection as augmented Bcl2 expression also attenuates
calcium overload (Fig. 2) [4,16–17].icular body weight ratio (LV/BW ratio); (C) myocyte area; (D) interstitial ﬁbrosis; (E)
r end diastolic arterial pressure (LVEDP); (I) rate of contraction (+LVdP/dtmax) and (J)
sus ISO.
Table 1
(A) Effect of drugs on TBARS, CK-MB, GSHPx, TNF-a, CRP, and BNP (n = 8). (B) Histopathological grading 1: no change; 2: focal change; 3: patchy change; 4: conﬂuent change; 5:
massive change.
Parameters TBARS (nmol/g tissue) CK-MB (U/L) GSPHx (U/mg protein) TNF-a (pg/mg protein) CRP (mg/ml) BNP (pg/ml)
NC 41.4 ± 8.3 251 ± 25 0.81 ± 0.07 28.2 ± 4.2 2.1 ± 0.3 79.9 ± 6.1
ISO 212.4 ± 13.8* 690 ± 39* 0.28 ± 0.09* 149.3 ± 12.4* 8.5 ± 0.7* 381.5 ± 53.0*
ISO + SB 117.2 ± 6.2 472 ± 49 0.59 ± 0.09§ 79.6 ± 9.2 4.7 ± 0.32§ 239.6 ± 36.8
ISO + SB + GSK-3bi 73.5 ± 4.4§ 259 ± 22§ 0.62 ± 0.8§ 51.1 ± 6.2§ 4.4 ± 0.9§ 132.8 ± 28.1§
Parameters (grading) Myonecrosis (1–5) Edema (1–5) Inﬂammation (1–5) Fiber disarray (1–5) Total (4–20)
NC 1 1 1 1 4
ISO 4.5 4 4.5 4.5 17.5*
ISO + SB 2.5 2 2 2 8.5
ISO + SB + GSK-3bi 2 1.5 1.5 2 7§
* P < 0.01 versus NC.
 P < 0.05 versus ISO.
§ P < 0.01 versus ISO.
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functions, 5-HT2BRB negatively regulated the inﬂammatory and
apoptotic pathways in isoproterenol-induced cardiac hypertrophy.
Isoproterenol-infusion attenuated the activity of Bcl2 (3-fold) and
ampliﬁed the activities of Bax (2.5-fold), IKK-b/NF-jB (2.5-fold),
CRP (4-fold), TNF-a (4-fold) and TUNEL positivity (9-fold);
which were subsequently attenuated by SB-204741 treatment
(P < 0.05) (Figs. 1E, 2 and3C1–C4andTable1A). Thiswas almostnor-
malized by co-treatment with SB-216763 (P < 0.01); thereby sug-
gesting a decisive role between 5-HT2BRB and GSK-3bi in tuningFig. 2. Effect of drugs on (A) 5-HT2B, GSK-3b, P-GSK-3b and b-catenin; (B) P-Akt, Akt, P-eN
expressions. Data are expressed as a ratio of normal control value (set to 100) (n = 8). ⁄Pinﬂammatory/apoptotic pathways. Importantly, transcription fac-
tor NF-jB, orchestrates an array of cellular responses including
inﬂammation, apoptosis and cellular proliferation by controlling a
complex network of NF-jB dependent gene products (TNF-a/IL-6/
IL-1b/IjB). One of the mechanisms for activation and intranuclear
translocation of NF-jB is IjB kinase (IKK) complex induction in re-
sponse to pro-inﬂammatory stimuli, leading to phosphorylation
anddegradationof IjBa and IjBb [18,19]. It has alsobeendelineated
that the phosphorylation of Akt/GSK-3b pathway regulates NF-jB
and b-catenin expressions [9], both of which are crucial regulatorsOS and eNOS; (C) Bax, NF-jBp65 and IKK-b and (D) Bcl2, MnSOD and Nox4 protein
< 0.01 versus NC and P < 0.05, §P < 0.01 versus ISO.
Fig. 3. Effect of drugs on light microscopic study (A1–A4, 20, scale bar 50 lm, hematoxylin and eosin staining), interstitial ﬁbrosis (B1–B4, 20, scale bar 50 lm, masson
trichome staining), TUNEL positivity (C1–C4, 20, scale bar 50 lm) and electron microscopic study (D1–D4, 4000, scale bar 1 lm) (n = 8). (1) Normal control; (2)
isoproterenol control; (3) isoproterenol + SB-204741; (4) isoproterenol + SB-204741 + GSK-3bi.
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inﬂammatory/anti-apoptotic effect in SB-216763 treated group
than SB-204741 group might be due to a higher phosphorylation
of Akt/GSK-3b/eNOS or a direct suppression of IKK-b/NF-jB/TNF-a
by SB-216763; as increased phosphorylation is cogently associated
with abrogation of inﬂammatory/apoptotic cascade. Moreover, it
might also be due to direct anti-inﬂammatory/anti-apoptotic
activity of SB-204741 or synergistic activity of SB-204741 with
SB-216763, as SB-216763 possesses strong anti-inﬂammatory/
anti-apoptotic effect [4,5,15,17].
Isoproterenol also ampliﬁes oxidative stress and ROS produc-
tion leading to enhanced lipid peroxidation in heart tissue. In line
with this assumption, we observed markedly (P < 0.01) increased
TBARS (5-fold) and Nox4 (2.8-fold) activities, (parameters of lipid
peroxidation and oxidant activity) accompanied by decreased
MnSOD (4-fold) and GSHPx (2.8-fold) activities (parameters of
antioxidant activity) in the isoproterenol challenged myocardium
(Fig. 2 and Table 1A). On the other hand, both SB-204741 and
SB-216763 attenuated oxidative stress, the effect being more pro-
nounced in SB-216763 group, which could be due to the combined
effect of 5-HT2BRB and GSK-3bi in combating oxidative stress in the
latter group; as GSK-3bi, has signiﬁcantly shown to attenuate the
oxidative stress in various animal models of drug discovery [1].
At a sub cellular level, the pronounced effect of SB-216763 can
be attributed to a higher Akt/GSK-3b/eNOS phosphorylation and
IKK-b/NF-kB suppression, reduced ROS production and/or ampliﬁ-
cation of myocardial antioxidant defense system in isoproterenoldamaged heart, which scavenges ROS and lipid peroxyl radicals,
and prevents myocardial damage [1,9,20].
Elevated serum BNP and CK-MB levels are the hallmark features
of cardiac hypertrophy and have been employed to establish
prognosis in cardiac hypertrophy and heart failure patients [21].
Recently, Liang and co-workers demonstrated that serotonin via
5-HT2BR stimulation upregulates BNP levels through NF-jB path-
way leading to cardiomyopathy, whilst 5-HT2BRB showed the
opposite results [22]. Consistent with this, our ﬁndings revealed
that both 5-HT2BRB (P < 0.05) and GSK-3bi (P < 0.01) improved
BNP (239.6 ± 36.8 and 132.8 ± 28.1 vs. 381.5 ± 53.0 pg/ml) and
CK-MB (472 ± 49 and 259 ± 22 vs. 690 ± 39 U/L) levels in isoprote-
renol-challenged myocardium, though the effect was more pro-
nounced in GSK-3bi group. This protective effect suggests a
superior and vital role of GSK-3bi in preserving the structural
integrity and preventing the leakage of these cardiac enzymes (Ta-
ble 1A).
To conclude, our molecular and functional ﬁndings strongly
suggest that Akt/GSK-3b is a crucial component of the biochemical
pathway responsible for 5-HT2BRB mediated anti-hypertrophic ef-
fect and presents a possible future therapeutic strategy speciﬁcally
aimed at treating myocardial hypertrophy.
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